The Washington Post examines a new model of cancer research, which focuses on precision medicine. Instead of finding drugs to treat cancers in specific organs, new trials seek to group patients together based on similar genetic mutations, regardless of cancer location.

This article in the Washington Post details how the NCI-MATCH research study is a prime example of a shift toward precision medicine. The trial is designed to be more efficient, faster and better able to match drugs with patients that are most likely to benefit from them.

An article by Reuters examines how pharmaceutical companies are using genome sequencing data to rapidly find new targets for drugs and therapies.

Kathy Giusti, member of the NIH Precision Medicine Initiative Working Group, writes a commentary in Forbes noting the need for a cultural shift to enable universal open data sharing in order to realize the full potential of precision medicine.

In a viewpoint commentary in JAMA, Dr. Euan Ashley outlines the need for a national effort on precision medicine.

A commentary in Nature examines a new way of carrying out clinical trials through the lens of precision medicine.

U.S. News and World Report examines how the Precision Medicine Initiative could fundamentally change the way we practice medicine and treat disease.

The Detroit News reports on how researchers at a Michigan children's hospital are using precision medicine to develop treatments for pediatric cancers.

Dr. Eric Green, director of NIH's National Human Genome Research Institute, gives five reasons we're at a turning point with precision medicine and provides an overview of the Precision Medicine Initiative for this article in Business Insider.

The New York Times reports on recently released genetic testing standards by the National Institute of Standards and Technology. As the Precision Medicine Initiative gains momentum, standards in genetic testing are vital to ensure accurate diagnoses across varying laboratories and testing methods.